LONDON (Reuters) - AstraZeneca, fighting a $106 billion bid approach from Pfizer, is talking to other companies as it seeks a partnering deal for its experimental Alzheimer's drug. Briggs Morrison, global head of medicines development, said AstraZeneca was talking to companies with more experience of Alzheimer's about a deal to share development of its so-called BACE inhibitor drug, which is set to enter late-stage Phase III development.
↧